“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”

Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.

Eric Crombez Biography and Net Worth

Chief Medical Officer and EVP of Ultragenyx Pharmaceutical

Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer and Executive Vice President, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions including Clinical Development, Clinical Operations, BioMetrics, Endpoint Development and Strategy, Regulatory Affairs and Drug Safety/Pharmacovigilance.

Previously, Dr. Crombez served as Ultragenyx’s Chief Medical Officer for gene therapy and inborn errors of metabolism, overseeing global clinical development and execution for the company’s gene therapy programs. At Dimension Therapeutics, Dr. Crombez served as Chief Medical Officer and led the clinical development efforts for clinical gene therapy programs in hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa). Previously, he worked at Shire in its Human Genetics Therapy business unit.

Dr. Crombez is an appointed industry representative on the FDA Cellular, Tissue and Gene Therapies Advisory Committee. Before joining industry, he was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.

What is Eric Crombez's net worth?: The estimated net worth of Eric Crombez is at least $2.87 million as of April 18th, 2024. Dr. Crombez owns 48,785 shares of Ultragenyx Pharmaceutical stock worth more than $2,867,582 as of September 19th. This net worth estimate does not reflect any other assets that Dr. Crombez may own. Learn More about Eric Crombez's net worth.
How do I contact Eric Crombez?: The corporate mailing address for Dr. Crombez and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Eric Crombez's contact information.
Has Eric Crombez been buying or selling shares of Ultragenyx Pharmaceutical?: Eric Crombez has not been actively trading shares of Ultragenyx Pharmaceutical during the last quarter. Most recently, Eric Crombez sold 142 shares of the business's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $44.10, for a transaction totalling $6,262.20. Following the completion of the sale, the executive vice president now directly owns 48,785 shares of the company's stock, valued at $2,151,418.50. Learn More on Eric Crombez's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 172,065 shares worth more than $7,219,323.08. The most recent insider tranaction occured on September, 3rd when CEO Emil D Kakkis sold 20,000 shares worth more than $1,117,000.00. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 9/3/2024.

Eric Crombez Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/18/2024	Sell	142	$44.10	$6,262.20	48,785

Eric Crombez Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $58.78

$58.21

$59.90

50 Day Range

MA: $51.46

$42.55

$59.36

2 Week Range

Now: $58.78

$31.52

$60.37

Volume

558,391 shs

Average Volume

791,931 shs

Market Capitalization

$4.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”

From InvestorPlace | Ad

Go here for the full details now.